CJC-1295 + DAC 5mg

CJC 1295 DAC 5mg — Precision-Engineered GHRH Analogue Peptide

CJC 1295 DAC is a structurally modified synthetic analogue of growth hormone releasing hormone (GHRH), engineered for extended circulatory stability and enhanced pharmacokinetic performance. Supplied as a lyophilised white powder in a single 5mg vial with a verified purity of ≥99%, this compound is formulated to the exacting standards required for in-vitro scientific research.

⚠️ Research Use Only. This product is intended exclusively for in-vitro scientific research. It is not approved for human or animal consumption, clinical use, or therapeutic application.

Table of Contents

1. Product Specifications
2. Mechanism of Action
3. DAC Technology — Extended Half-Life
4. Research Applications
5. Reconstitution and Storage
6. FAQ

Product Specifications

Mechanism of Action

CJC 1295 with DAC functions as a growth hormone (GH) secretagogue — stimulating the pituitary gland to increase endogenous GH secretion and consequently elevating insulin-like growth factor 1 (IGF-1) levels. A defining feature of this analogue is its capacity to preserve the natural pulsatile pattern of GH release, distinguishing it from compounds that produce continuous, non-physiological GH elevation.

The peptide’s structural modifications relative to endogenous GHRH confer resistance to enzymatic degradation. This resistance is a direct result of the incorporation of D-amino acid substitutions and the addition of the Drug Affinity Complex component at the C-terminus.

Research conducted in both animal and human models has confirmed GH and IGF-1 stimulation following administration, forming the mechanistic basis for the compound’s ongoing investigation across multiple physiological domains.

DAC Technology — Extended Half-Life

The distinguishing feature of CJC 1295 w DAC relative to other GHRH analogues is the Drug Affinity Complex (DAC) technology integrated into its molecular structure.

DAC is attached to the CJC-1295 molecule via a lysine linker at the C-terminal end. This modification enables the peptide to form a covalent bond with the blood protein albumin during systemic circulation. The albumin binding mechanism provides two critical advantages for research applications.

First, it protects the peptide from proteolytic degradation by circulating enzymes — a primary limitation of unmodified GHRH and shorter-acting analogues. Second, the albumin-bound fraction acts as a slow-release reservoir, significantly extending the compound’s effective half-life relative to both natural GHRH and analogues without DAC modification.

This extended half-life is the principal pharmacokinetic distinction between cjc 1295 with dac and CJC-1295 formulations without the DAC component — a distinction of direct relevance to research protocols examining sustained GH axis stimulation.

Research Applications

Published and ongoing research involving CJC-1295 DAC spans several physiological domains. Investigators have examined its utility in the following in-vitro and in-vivo research contexts:

• GH secretagogue activity and pulsatility preservation studies
• IGF-1 axis modulation research
• Metabolic rate and body composition investigation
• Musculoskeletal tissue response studies
• Sleep architecture and GH secretion correlation research
• Cellular repair and regenerative biology applications

All research applications are conducted within the bounds of approved in-vitro and preclinical frameworks. This compound is not approved for therapeutic use in any jurisdiction.

Reconstitution and Storage

Reconstitute with NaCl, sterile water or bacteriostatic water at 1ml per vial. Add solvent slowly along the vial wall — do not shake. Allow to dissolve by gentle rotation.

Store lyophilised powder at −20°C. Once reconstituted, store at 4°C and use within the recommended timeframe consistent with your research protocol. Protect from light and repeated freeze-thaw cycles.

Explore other precision-engineered research peptides in our Longevity and Anti-Age, Muscle Growth and Weight Loss research categories.

FAQ

What is CJC 1295 DAC? CJC 1295 DAC is a synthetic analogue of growth hormone releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) component. The DAC enables albumin binding in circulation, significantly extending the peptide’s half-life relative to unmodified GHRH and non-DAC analogues. It functions as a GH secretagogue, stimulating GH and IGF-1 production while preserving the natural pulsatile pattern of GH release. Available as a 5mg lyophilised powder for in-vitro scientific research.

What is the difference between CJC 1295 with DAC and CJC 1295 no DAC? The fundamental distinction between CJC 1295 with DAC and CJC 1295 no DAC lies in pharmacokinetics. The DAC component enables albumin binding, extending the effective half-life from hours to several days — making it relevant for research protocols requiring sustained GH axis stimulation. CJC-1295 without DAC has a shorter half-life and clears the system more rapidly, making it more suitable for protocols examining acute GH pulsatility. Both are research compounds only.

What does CJC-1295 DAC dosage research involve? CJC-1295 DAC dosage investigations in published research have typically examined dose-response relationships in animal models and Phase I/II human studies. Research parameters vary significantly across protocols. This product is supplied for in-vitro scientific research only — it is not approved for human administration, and no dosage guidance is provided or implied for clinical or personal use.

What is CJC-1295 DAC dosage per day in research contexts? CJC-1295 DAC dosage per day as examined in published preclinical and clinical research varies by study design, species and target endpoint. Investigators working within approved research frameworks reference published literature and institutional protocols to establish dosing parameters. This compound is not approved for human use and no therapeutic dosage recommendation is made here.

How much CJC 1295 DAC should I take? This product is intended exclusively for in-vitro scientific research and is not approved for human consumption or therapeutic use. How much CJC 1295 DAC should I take is not a question this product is designed to answer — administration in humans falls outside the intended use of this compound. Researchers conducting approved studies should reference published methodology and institutional guidelines.

How should CJC-1295 + DAC be reconstituted for research? For in-vitro research applications, reconstitute CJC-1295 + DAC with NaCl, sterile water or bacteriostatic water at 1ml per vial. Add solvent slowly along the vial wall and allow the powder to dissolve by gentle rotation. Do not vortex or shake vigorously. Store reconstituted solution at 4°C and protect from light.